Delivery Order SPE2DB20D1109-SPE2DB25FP70Y
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,112.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed price order represents a single delivery transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract was executed on September 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $39,157.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL pen injections on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was made on a non-set-aside, competitive basis and will be...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $7,999.09 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 10, 2025, with completion scheduled for September 11, 2025. This competitive award, issued without set-aside designation, represents a firm fixed price delivery order for pharmaceutical supply to support federal medical procurement needs. The contract specifies performance in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $15,525.73 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 24, 2025, with completion scheduled for June 25, 2025. This non-competitive delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a delivery order valued at $37,758.82 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a $10,654.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with completion targeted for July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP70YDelivery Order
The Defense Logistics Agency awarded a $17,361.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen auto-injectors on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price contract represents a competitively awarded delivery order with no set-aside designation, supporting federal medical procurement needs for military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Dupixent is a biologic medication used to treat severe eczema, asthma, and other inflammatory conditions, and this order demonstrates the contractor's role in providing specialized brand-name medications to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.4k | 9/8/25 |